Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.61 |
| ▸ | CTSK | P43235 | 6/20 | 0.61 |
| ▸ | PPARG | P37231 | 1/20 | 0.58 |
| ▸ | PPARA | Q07869 | 1/20 | 0.58 |
| ▸ | ACE | P12821 | 2/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 3/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | REN | P00797 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18228983 | 1.00 | CTSS (0.61) | CTSSCTSKPPARGPPARAACE | |
| SCHEMBL3821796 | 0.92 | PPARA (0.60) | CTSSCTSKPPARGPPARAACE | |
| SCHEMBL199415 | 0.90 | PPARA (0.68) | CTSSCTSKPPARGPPARAACE | |
| SCHEMBL441283 | 0.90 | PPARA (0.68) | CTSSCTSKPPARGPPARAACE | |
| SCHEMBL440723 | 0.90 | PPARA (0.68) | CTSSCTSKPPARGPPARAACE | |
| SCHEMBL18229063 | 0.89 | CTSL (0.51) | CTSSCTSKPPARGPPARAACE | |
| SCHEMBL3840582 | 0.88 | PPARG (0.58) | CTSSCTSKPPARGPPARAACE | |
| SCHEMBL22962027 | 0.87 | CTSS (0.69) | CTSSCTSKPPARGPPARAACE | |
| SCHEMBL18229001 | 0.87 | CTSL (0.51) | CTSSCTSKACEITGB3CTSL | |
| SCHEMBL20187248 | 0.87 | CTSL (0.51) | CTSSCTSKACEITGB3CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3280721-B1 | PROCESS FOR PREPARATION OF NITROGEN MUSTARD DERIVATIVES | ONCOPEPTIDES AB (SE) | 2020-07-22 | — | — | EP | disclosed |
| US-10287316-B2 | Process for preparation of nitrogen mustard derivatives | ONCOPEPTIDES AB (SE) | 2019-05-14 | — | — | US | disclosed |
| US-20180148473-A1 | PROCESS FOR PREPARATION OF NITROGEN MUSTARD DERIVATIVES | ONCOPEPTIDES AB (SE) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148473-A1 | PROCESS FOR PREPARATION OF NITROGEN MUSTARD DERIVATIVES | CBR3, GRHPR, CTH | CTSS 905/4885CTSK 1803/4885PPARG 630/4885 |
| US-10287316-B2 | Process for preparation of nitrogen mustard derivatives | CBR3, GRHPR, CTH | CTSS 905/4885CTSK 1803/4885PPARG 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.